Covance To Open Its Own Preclinical Facility In Shanghai After Abandoning Plans To Create Joint Drug Testing Facility With WuXi
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Princeton-headquartered contact research organization Covance is investing $20-25 million to build a preclinical laboratory in Shanghai, the company's second such research facility in Shanghai
You may also be interested in...
Charles River-WuXi PharmaTech Deal Transforms China's CRO Landscape
Charles River's acquisition of WuXi PharmaTech, valued at $1.6 billion, is the largest merger so far in China's healthcare space and is likely to drastically change the CRO playing field in China
Charles River-WuXi PharmaTech Deal Transforms China's CRO Landscape
Charles River's acquisition of WuXi PharmaTech, valued at $1.6 billion, is the largest merger so far in China's healthcare space and is likely to drastically change the CRO playing field in China
Charles River, Parexel, PPD: PharmAsia News CRO Earnings Roundup
The largest contract research organizations have begun to spread their reach into emerging markets to keep pace with their big pharma customers